Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q2 2025 Earnings Presentation
23 slides from Hls Therapeutics's earnings presentation, Aug 14, 2025
Slide 1: Q2 2025 Conference Call
Q2 2025 Conference Call August 14, 2025 Craig Millian, CEO John Hanna, CFO Brian Walsh, CCO TSX - HLS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Key Themes
Key Themes 1. Executing on our base business 2. Building a leading Canadian-based cardiovascular franchise 3. Strengthening our financial foundation Toronto Stock Exchange (TSX) - HLS HLS THERAPEUTICS INC. 3
Slide 4: Executing on our Base Business
Executing on our Base Business Revenue: Product revenues for Canada and US up YTD in local currencies Q2: $14.2M YTD: $26.8M OpEx is down 19% YTD (excl cost of sales) Cash from operations: Q2: $4.6M YTD: $8.1M Adjusted EBITDA is up 29% YTD Adjusted EBITDA: Q2: $5.2M YTD: $9M Cash from operations is
Slide 5: Expanding our Cardiovascular Franchise
Expanding our Cardiovascular Franchise Overview Value Proposition Timeline Oral CV medicines Differentiated Mechanism of Action Q4 24: New Drug Submissions filed FDA approved 2020 (lower LDL-C) Strong CV outcomes data Q4 25: Health Canada approval expected Label expanded 2024 (reduce CV risk) Sizabl
Slide 6: Strengthening our Financial Foundation
Strengthening our Financial Foundation Strong balance Reduced bank Reduced annual sheet and cash debt by 34% interest expense flow increases since Q2 2024 $1.6M YTD 2025 flexibility for strategic capital allocation Toronto Stock Exchange (TSX) - HLS HLS THERAPEUTICS INC. 6
Slide 7: Life-changing medicine for Treatment Resistant Schizophrenia
Life-changing medicine for Treatment Resistant Schizophrenia Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 8: Executing on Regional Strategies
Executing on Regional Strategies Western Canada market share growth through CSAN differentiation Ontario improve Clozaril utilization amongst TRS patients Quebec leverage CSAN support for patient retention U.S. leverage specialty pharma partnership *Nova Scotia strategy similar to Ontario *New Bruns
Slide 9: A New Paradigm in the Treatment of Cardiovascular Risk
A New Paradigm in the Treatment of Cardiovascular Risk Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 10: Drivers of 2H 2025 Growth
Drivers of 2H 2025 Growth Strengthened Team Broadening Access Stabilizing Payer Mix Changes in sales Expanded public Improved private plan leadership and field force reimbursement in Western patient retention and personnel Canada & Atlantic Canada targeting Toronto Stock Exchange (TSX) - HLS Provide
Slide 11: Continued Prescribing Growth
Continued Prescribing Growth TRx Units Since Launch 160000 23% Q2 increase in unit demand* 140000 25% YTD increase* 120000 *Compared to 2024 periods 100000 80000 32% Q2 increase in total prescribers 60000 40000 20000 31% Q2 increase in consistent prescribers 0 2020 2021 2022 2023 2024 TTM 06-30-2025
Slide 12: NEXLETOL & NEXLIZET: LDL Pathway Innovation
NEXLETOL & NEXLIZET: LDL Pathway Innovation NEXLETOL: Bempedoic acid monotherapy Daily oral non-statin treatment to lower LDL Not activated in skeletal muscle Does not raise glucose NEXLIZET: Combination therapy Reduces hsCRP Bempedoic acid + ezetimibe Single daily pill maximizes LDL reduction Use w
Slide 13: Compelling Trial Data
Compelling Trial Data CLEAR OUTCOMES TRIAL RESULTS: CV Risk Reduction Primary Prevention* LDL-C Reduction Nonfatal MI 30% of patients 27% enrolled have not had RRR their first event but are at high risk 38% HR, 0.73 (95% CI: 0.62-0.87) Coronary Revascularization MACE-4 (nonfatal MI, coronary revascu
Slide 14: Canadian Market Opportunity
Canadian Market Opportunity ~200K >300K >500K Patients not at target LDL-C Canadians unable to take Canadian levels despite statin/ezetimibe recommended statin therapy patients therapy Source: IQVIA data and primary market research estimates 600-700K patients on statin/ezetimibe therapy of which 30-
Slide 15: Launch will Leverage Current CV Infrastructure
Launch will Leverage Current CV Infrastructure Leverage current High overlap with Minimal additional field footprint Vascepa prescribers OpEx required Q4 2025 Q2 2026 2027 Health Canada Commercial launch Public listings approval expected with meaningful private coverage Long patent runway: Vascepa t
Slide 16: Three products, one goal: reducing cardiovascular risk for more Canadians
Three products, one goal: reducing cardiovascular risk for more Canadians Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update HLS THERAPEUTICS INC.
Slide 17: Financial Review: Strengthening Foundation to Support Growth
Financial Review: Strengthening Foundation to Support Growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 18: Revenue Growth from Marketed Products
Revenue Growth from Marketed Products YTD Marketed Product Revenue (USD$000’s) 25,000 20,000 6% YTD growth (in CAD) Canadian product sales of Vascepa and Clozaril 15,000 2% 2% YTD growth (in USD) 10,000 5,000 US sales of Clozaril 0 YTD 2024 YTD 2025 Toronto Stock Exchange (TSX) - HLS Provided as par
Slide 19: Reducing Expenses, Improving Margins & Generating Cash Flow
Reducing Expenses, Improving Margins & Generating Cash Flow YTD Operating Expenses YTD Adjusted EBITDA YTD Cash from Operations (excluding Cost of Sales) ($000’s) (excluding Royalties) ($000’s) ($000’s) 16,000 9,000 9,000 14,000 8,000 8,000 7,000 7,000 12,000 6,000 6,000 10,000 5,000 5,000 8,000 19%
Slide 20: Operational Changes Delivering Improved Profitability
Operational Changes Delivering Improved Profitability Adjusted EBITDA excluding Royalties (trailing twelve month period ended) 20000 18000 16000 14000 12000 $(000s) 10000 8000 6000 4000 2000 0 Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains
Slide 21: Stronger Balance Sheet & Diversified Capital Allocation
Stronger Balance Sheet & Diversified Capital Allocation Summary Balance Sheet & Capitalization De-levering the Balance Sheet Made $8.5M principal debt payment in Q2 2025 (US$ millions) At Dec 31, 2024 At Jun 30, 2025 >$11M of principal debt payments YTD 2025 Cash and Cash Equivalents 17.5 12.2 1 Sen
Slide 22: YTD Summary
YTD Summary 1 Grew product portfolio sales 2 Reduced operating expenses 3 De-levered the balance sheet and increased financial flexibility 4 Executed share buyback 5 In-licensed NEXLETOL & NEXLIZET for cardiovascular market Building a foundation for long-term value creation through profitable growth
Slide 23: Q2 2025 Conference Call
Q2 2025 Conference Call August 14, 2025 Craig Millian, CEO John Hanna, CFO Brian Walsh, CCO TSX - HLS